Breaking: Galera Therapeutics Tumbles on FDA Setback
- August 09th, 2023
- 278 views
Shares of Galera Therapeutics, Inc.? (Nasdaq: GRTX) plunged over 70% in after-hours trading as the company received a Complete Response Letter (CRL) from the FDA, addressing its New Drug Application (NDA) for avasopasem manganese, a potential treatment for severe oral mucositis in head and neck cancer patients undergoing standard-of-care treatment.
The FDA's communication cited insufficiency in data from the Phase 3 ROMAN trial and supporting GT-201 trial to establish avasopasem's effectiveness and safety. An additional clinical trial will be required for resubmission.
In response, Galera stated its intention to request a Type A meeting with the FDA and outlined plans to enhance financial stability by cutting its workforce by approximately 70%.
$GRTX was trading at $0.38 in after-hours, down $1.85 (-82.59%) following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login